Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Fulvestrant

Criteria

Inclusion Criteria:

• Provision of written informed consent

• Postmenopausal woman who fulfils any one of the following criteria:

• Histological or cytological confirmation of breast cancer

• Estrogen receptor positive (ER+) or progesterone receptor positive (PgR+).

Exclusion Criteria:

• Having received any one of the following therapy for advanced or recurrent breast cancer

• 2 or more regimens of hormonal therapy or immunotherapy or 2 or more regimens of chemotherapy, etc